Belinostat (PXD101)

inquiry

Cat No.

CEI-1242

Description

Belinostat (PXD101) is a novel inhibitor of pan-HDAC with an IC50 value of 27 nM.

Product Overview

Belinostat (also known as PXD101) is a novel and potent hydroxamate-type inhibitor of histone deacetylase (HDAC) that inhibits the activity of HDAC in Hela cell extracts with 50% inhibition concentration IC50 value of 27 nM. Belinostat has been found to significantly increase the acetylation of histones H3 and H4 and exerts cytotoxicity in a wide range of tumor cell lines. In the treatment of urothelial carcinoma cell lines, belinostat dose-dependently inhibits proliferation in 5637, T24, J82 and RT4 cells with IC50 values of 1.0 μM, 3.5 μM, 6.0 μM and 10 μM respectively; while, in prostate cancer cell lines, it inhibits cancer cell growth with IC50 values ranging from 0.5 to 2.5 μM.

CAS_No

414864-00-9

Molecular Weight

318.35

Purity

0.991

Storage

Store at -20°C

Synonyms

PXD-101, PXD 101, PX105684, PX-105684

Targets

HDAC

IC50

27 nM

Molecular Formula

C15H14N2O4S

Chemical Name

(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide

Solubility

Soluble in DMSO > 10 mM

Shipping Conditions

Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request

Name:

Email *

Phone:*

Company/Institution:

Country or Region:

Quantity:

Services & Products Interested *

Project Description:

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Products

Online Inquiry